{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:37:10Z","timestamp":1780508230397,"version":"3.54.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pregnancy can lead to the recurrence or exacerbation of immune thrombocytopenia (ITP). Currently, first-line treatments of low-dose corticosteroids or intravenous immunoglobulin are considered safe and effective for both pregnant women and fetuses. However, there is no well-established treatment option for patients who are refractory to these medications. Herein, we report a case of a 31-year-old pregnant woman with recurrent and refractory ITP who was safely and effectively treated with hetrombopag, with no influence on the infant's platelet count. This case explores a new treatment option for the management of recurrent and refractory ITP in pregnancy.<\/jats:p>","DOI":"10.3389\/fmed.2025.1528131","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:53:25Z","timestamp":1739861605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hetrombopag treatment for immune thrombocytopenia in pregnancy refractory to corticosteroids and intravenous immunoglobulin: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Luyi","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e70008","DOI":"10.1111\/aji.70008","article-title":"Immune thrombocytopenic purpura and maternal and neonatal outcomes during pregnancy: a systematic review and meta-analysis","volume":"92","author":"Zhang","year":"2024","journal-title":"Am J Reprod Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/bjh.19230","article-title":"Immune thrombocytopenia (ITP) in pregnancy","volume":"204","author":"Bussel","year":"2024","journal-title":"Br J Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.5603\/GP.a2021.0147","article-title":"Thrombocytopenia in pregnant women","volume":"92","author":"Ruszala","year":"2021","journal-title":"Ginekol Pol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e67449","DOI":"10.7759\/cureus.67449","article-title":"Navigating primary immune thrombocytopenia during pregnancy with management strategies and considerations: a comprehensive review","volume":"16","author":"Dahiphale","year":"2024","journal-title":"Cureus."},{"key":"B5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/s12884-023-06134-y","article-title":"Recombinant human thrombopoietin therapy for primary immune thrombocytopenia in pregnancy: a retrospective comparative cohort study","volume":"23","author":"Lin","year":"2023","journal-title":"BMC Pregn Childb."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3000605231187950","DOI":"10.1177\/03000605231187950","article-title":"Application of recombinant human thrombopoietin in pregnant women with immune thrombocytopenia: a single-center experience of four patients and literature review","volume":"51","author":"Yu","year":"2023","journal-title":"J Int Med Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ajh.26743","article-title":"Romiplostim use in pregnant women with immune thrombocytopenia","volume":"98","author":"Bussel","year":"2023","journal-title":"Am J Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e22505","DOI":"10.7759\/cureus.22505","article-title":"Use of eltrombopag for the first trimester pregnancy complicated with refractory idiopathic thrombocytopenic purpura: a case report and literature review","volume":"14","author":"Shibata","year":"2022","journal-title":"Cureus."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00277-024-05826-5","article-title":"Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial","volume":"103","author":"Mei","year":"2024","journal-title":"Ann Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3892\/br.2024.1732","article-title":"Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Shen","year":"2024","journal-title":"Biomed Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"Xie","year":"2018","journal-title":"J Cell Mol Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"20406207221085197","DOI":"10.1177\/20406207221085197","article-title":"A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy","volume":"13","author":"Peng","year":"2022","journal-title":"Ther Adv Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1182\/blood.2023020726","article-title":"How I treat thrombocytopenia in pregnancy","volume":"143","author":"Fogerty","year":"2024","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/hematology.2022000375","article-title":"Thrombocytopenia in pregnancy","volume":"2022","author":"Pishko","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Prog."},{"key":"B17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4274\/tjh.galenos.2024.2024.0101","article-title":"Management of primary immune thrombocytopenia: Turkish modified Delphi-based consensus statement for special considerations","volume":"41","author":"\u00dcmit","year":"2024","journal-title":"Turk J Haematol."},{"key":"B18","first-page":"2093","volume-title":"Williams Hematology, 10th ed, Chapter 116 Thrombocytopenia","author":"Kaushansky","year":"2021"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hemonc.2021.05.004","article-title":"Use of thrombopoietin receptor agonists in pregnancy: a review of the literature","volume":"15","author":"Howaidi","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s13312-020-1966-8","article-title":"Immune thrombocytopenia: American Society of Hematology guidelines, 2019","volume":"57","author":"Sahi","year":"2020","journal-title":"Indian Pediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/bjh.19161","article-title":"Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists","volume":"203","author":"Rottenstreich","year":"2023","journal-title":"Br J Haematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1182\/blood.2020007594","article-title":"Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study","volume":"136","author":"Michel","year":"2020","journal-title":"Blood."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1528131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:53:27Z","timestamp":1739861607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1528131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":23,"alternative-id":["10.3389\/fmed.2025.1528131"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1528131","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"article-number":"1528131"}}